A Phase II, Single-centre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's Monovalent H1N1 Influenza Virus Vaccine in Healthy Adults Aged 18 to < 65 Years.

Trial Profile

A Phase II, Single-centre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's Monovalent H1N1 Influenza Virus Vaccine in Healthy Adults Aged 18 to < 65 Years.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs CSL 425 (Primary)
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Most Recent Events

    • 24 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jan 2010 Results were presented in the New England Journal of Medicine.
    • 17 Dec 2009 Interim results were published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top